The usefulness of extended lymphadenectomy and molecular staging for urothelial carcinoma patients who undergo nephroureterectomy or total cystectomy

The usefulness of extended lymphadenectomy and molecular staging for urothelial carcinoma patients who undergo nephroureterectomy or total cystectomy - The usefulness of extended lymphadenectomy and molecular staging for urothelial carcinoma patients who undergo nephroureterectomy or total cystectomy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002519

Enrollment

100

Registered

2009-09-24

Start date

2009-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial carcinoma patients who undergo nephroureterectomy or total cystectomy

Interventions

Extended lymphadenectomy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Urothelial carcinoma patients who undergo nephroureterectomy or total cystectomy , had written informed consent

Exclusion criteria

Exclusion criteria: No informed consent

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Disease specific survival Prognostic factor of molecular staging using RT-PCR method	—

Countries

Japan

Contacts

Public ContactIsco Hara, M.D.

Wakayama Medical University Urology

hara@wakayama-med.ac.jp073-441-0637

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026